| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SIRPA |
| Uniprot No | P78324 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-370aa |
| 氨基酸序列 | EEELQVIQPDKSVLVAAGETATLRCTATSLIPVGPIQWFRGAGPGRELIY NQKEGHFPRVTTVSDLTKRNNMDFSIRIGNITPADAGTYYCVKFRKGSPD DVEFKSGAGTELSVRAKPSAPVVSGPAARATPQHTVSFTCESHGFSPRDI TLKWFKNGNELSDFQTNVDPVGESVSYSIHSTAKVVLTREDVHSQVICEV AHVTLQGDPLRGTANLSETIRVPPTLEVTQQPVRAENQVNVTCQVRKFYP QRLQLTWLENGNVSRTETASTVTENKDGTYNWMSWLLVNVSAHRDDVKLT CQVEHDGQPAVSKSHDLKVSAHPKEQGSNTAAENTGSNER |
| 预测分子量 | 64 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SIRPA重组蛋白的3篇参考文献示例(内容为示例，具体文献需根据实际研究补充)：
---
1. **文献名称**: *"Engineered SIRPA Variants as CD47-Blocking Agents for Synergistic Cancer Immunotherapy"*
**作者**: Alvey, C. M. et al.
**摘要**: 研究报道了一种工程化SIRPA重组蛋白(SIRPAvariant)，通过阻断肿瘤细胞表面CD47的“别吃我”信号，增强巨噬细胞对癌细胞的吞噬作用。实验表明，该重组蛋白与PD-1抑制剂联用可显著抑制肿瘤生长。
2. **文献名称**: *"SIRPA-CD47 Signaling in Neurological Disease and Therapeutics"*
**作者**: Okazawa, H. et al.
**摘要**: 探讨SIRPA重组蛋白在神经退行性疾病中的作用，发现其通过调控小胶质细胞CD47/SIRPA信号通路，减少神经元损伤，为阿尔茨海默病等疾病提供潜在治疗策略。
3. **文献名称**: *"Structural Basis of SIRPA Function in Immune Regulation"*
**作者**: Veillette, A. et al.
**摘要**: 解析了SIRPA重组蛋白的晶体结构，阐明其与CD47结合的分子机制，揭示其在免疫检查点中的关键作用，为开发靶向药物提供结构生物学依据。
---
如需真实文献，建议通过PubMed或Google Scholar搜索关键词“SIRPA recombinant protein”“CD47 blockade”等获取最新研究。
**Background of SIRPA Recombinant Protein**
Signal Regulatory Protein Alpha (SIRPA) is a transmembrane glycoprotein belonging to the immunoglobulin superfamily, primarily expressed in myeloid cells (e.g., macrophages, dendritic cells) and neurons. It plays a critical role in modulating immune responses and maintaining cellular homeostasis. SIRPA interacts with its ligand CD47. a widely expressed "don't eat me" signal, to regulate phagocytic activity. This SIRPA-CD47 axis ensures self-recognition, preventing immune cells from attacking healthy host cells while enabling clearance of CD47-low pathological cells, such as aged or cancerous cells.
Recombinant SIRPA proteins are engineered versions of the extracellular domain of SIRPA, produced using expression systems like mammalian or bacterial cells. These proteins retain the functional immunoglobulin variable (IgV) domain responsible for CD47 binding, enabling studies on receptor-ligand interactions. Researchers often fuse SIRPA with tags (e.g., Fc, His-tag) to enhance stability, purification, or detection.
In therapeutic contexts, recombinant SIRPA is explored to augment cancer immunotherapy. By competitively blocking CD47 on cancer cells, it disrupts the "don't eat me" signal, promoting macrophage-mediated tumor phagocytosis. This approach synergizes with checkpoint inhibitors (e.g., anti-PD-1) or targeted therapies. Additionally, SIRPA-based tools are used in neurodegenerative disease research, as SIRPA-CD47 signaling influences synaptic pruning and microglial activity.
Despite its potential, challenges remain, including optimizing binding affinity and minimizing off-target effects. Ongoing studies focus on engineering high-avidity SIRPA variants or bispecific molecules to improve therapeutic efficacy. As a research tool, recombinant SIRPA aids in deciphering immune evasion mechanisms and developing biomarkers for diseases like cancer or Alzheimer’s. Its dual role in immunity and neural function underscores its broad biomedical relevance.
×
